

C.V

(Shaymnaa Mahmoud Yahya, PhD)

Assistant Professor, National Research Centre.

List of some publications.

1. **Shaymaa M. M. Yahya, Ahmed R. Hamed, Mohamed Emara, Maha M. Soltan, Gamal Eldein F. Abd-ellatef, Salma M Abdelnasser.** . Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells. Tumor Biol 2015, DOI 10.1007/s13277-015-4426-7.
2. **Shaymaa M.M. Yahya, Ghada H. Elsayed** . A summary for molecular regulations of miRNAs in breast cancer. Clinical Biochemistry 48 (2015) 388–396.
3. **Emad F. Eskander , Ahmed A. Abd-Rabou, Mervat S. Mohamed Shaymaa M.M. Yahya, Ashraf El Sherbini, , Olfat G. Shaker** The potential impact of P53 and apo-1 genetic polymorphism on hepatitis genotype 4 susceptibility. Gene, 2014.
4. ***Mervat M El-Gendy, Ahmed MA El-bondkly, Shaymaa MM Yahya*** .Production and evaluation of antimycotic and anti hepatitis C virus potential of fusant MERV6270 derived from Mangarove endophytic fungi using novel substrates of agro-industrial wastes . Applied Biochemistry and Biotechnology 2014;174(8):2674-701.
5. **Shaymaa MM Yahya**. THE IMPACT OF HCV KNOCKDOWN ON STAT3 AND ADI1 EXPRESSION IN HUMAN CON1 CELLS. WJPR, 2014, 3(6): 198-203.
6. **Shaymaa MM Yahya**. DOES STAT3 KNOCKDOWN AFFECT HCV REPLICATION. WJPPS, 2014, 3(9): 1324-1329.

7. **Emad F. Eskander , Ahmed A. Abd-Rabou, Shaymaa M.M. Yahya, Ashraf El Sherbini, , Mervat S. Mohamed, , Olfat G. Shaker.** P53 codon 72 single base substitution in viral hepatitis C and hepatocarcinoma incidences. ? Indian Journal of Clinical Biochemistry , 2014, 29, (1): 3-7
8. **Emad F. Eskander , Ahmed A. Abd-Rabou, Shaymaa M.M. Yahya, Ashraf El Sherbini, Mervat S. Mohamed, , Olfat G. Shaker.** Correlation and multiple regression analyses of pituitary growth hormone and hepatic activities in hepatitis C infection and interferon response, Ind J Clin Biochem , 2013, 28(4):348–357
9. **Emad F. Eskander , Ahmed A. Abd-Rabou, Olfat G, Shaker , Mervat S. Mohamed, Shaymaa M.M. Yahya, Olfat G. Shaker.** Does HCV Patients Who Have BCL2 43Ala Genotype and Normal GH1 Levels Can Achieve Response to IFN Based Therapy? Indian Journal of Clinical Biochemistry, 2012, 27(4):344–350.
10. **Emad F. Eskander , Ahmed A. Abd-Rabou, Shaymaa M. M. Yahya, Olfat G, Shaker , Mervat S. Mohamed.** Does Interferon and Ribavirin Combination Therapy Ameliorate Growth Hormone Deficiency in HCV Genotype-4 Infected Patients? Clinical Biochemistry (2012), 45: 3-6.

11. **Olfat G. Shaker , Emad F. Eskander , Shaymaa MM Yahya, Mervat El-Sayed , Ahmed Abdrabou.** Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients, Clinica Chimica Acta (2011), 412: 593–598.
12. **Awatif M. Abd El-Maksoud, Mohammed H. El Hefnawy, Abdel-Rahman B. Abdel-Ghaffar, Emad F. Eskander, Hanaa H. Ahmed, Dina M. Seoudi, Shaymaa M. M. Yahya, Ibrahim H. Kamal.** Adiponectin, leptin, and lipid profile in type 1 diabetic children and adolescents. Journal of Clinical Lipidology (2009) 3: 269–274.
13. **Awatif M. Abd El-Maksoud , Mohammed H. El Hefnawy , Shaymaa M.M. Yahya , Dina M. Seoudi, Abdel-Rahman B. Abdel-Ghaffar , Emad F. Eskander.** Early predictors of microvascular complications in type 1 diabetic patients, Clinical Biochemistry (2009), 42:1401–1406.